Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07807995
PHASE3
A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
Sponsor: Vertex Pharmaceuticals Incorporated
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).
Official title: A Phase 3, Single-Arm, Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
605
Start Date
2026-09-18
Completion Date
2029-12-28
Last Updated
2026-09-08
Healthy Volunteers
No
Conditions
Interventions
DRUG
Povetacicept
Subcutaneous injection administration.